DR.ANIL BATTA
Abstract
Acute myeloid leukemia (AML) is characterized by blocked myeloid-lineage differentiation and accumulation of myeloid blast cells in the bone-marrow that results in catastrophic bone-marrow failure. AML is a highly heterogeneous disease driven by different mutations that affect signaling pathways, transcription factors, and epigenetic regulators. The current treatment for AML starts with induction chemotherapy ,followed by a few cycles of consolidation chemotherapy or an allogeneic hematopoietic stem–cell transplantation (allo-HSCT). The disease’s prognosis and outcomes in adults and the elderly, who account for the majority of AML patients, remains poor. The ever-growing advancement in genomic technologies allows us to have an unprecedented view of the spectrum and frequency of mutations, their clonal nature, and their evolution during progression of the disease and the epigenetic modulation of the disease. Incorporating ex vivo highthroughput drug screening has the potential to tailor therapy for patients. This review provides an overview on novel targeted therapies, approved drugs, and ongoing clinical trials with the aim of personalizing AML therapy